Welcome to our dedicated page for Davita SEC filings (Ticker: DVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DaVita Inc. (NYSE: DVA) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its kidney care operations, capital structure and governance. This page aggregates those SEC filings and pairs them with AI-powered tools to help readers understand the implications for the company’s dialysis and integrated kidney care business.
For DaVita, current reports on Form 8-K are particularly informative. Recent 8-K filings describe quarterly financial results, including consolidated revenues, operating income, cash flow and key U.S. dialysis metrics, as well as board actions such as increases to the company’s share repurchase authorization. Other 8-Ks outline material definitive agreements, including amendments to DaVita’s senior secured credit facilities that establish new term loan and revolving credit arrangements and explain how proceeds may be used for refinancing, working capital and general corporate purposes.
Investors following DVA can also use SEC filings to track topics such as share repurchases, debt issuance and integrated kidney care strategy. Disclosures around authorization levels for repurchase programs, limitations under credit agreements and the company’s approach to capital allocation appear in these documents. Filings related to financial results provide context on DaVita’s role as a comprehensive kidney care provider, its global network of outpatient dialysis centers and its participation in value-based care models.
On this page, AI-generated summaries highlight the main points of each filing, explain technical language and draw attention to items that may matter to shareholders, such as changes in credit facilities, repurchase authorizations or reported operating performance. Users can quickly locate DaVita’s quarterly and annual reports when available, review Form 8-K disclosures and examine any insider-related filings, while relying on AI assistance to interpret how these regulatory documents relate to the company’s kidney care operations and financial profile.
BERRY CHRISTOPHER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. Chief Accounting Officer Christopher Michael Berry reported receiving a grant of 3,649 shares of Common Stock as a compensation-related award, recorded at $0.00 per share rather than an open-market purchase.
According to the footnote, these are restricted stock units scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to the applicable award terms. After this award, Berry directly holds 19,640 shares of DaVita common stock.
DaVita Inc. CFO and Treasurer Joel Ackerman reported routine equity compensation and related tax-withholding transactions. He received a grant of 15,427 Stock Appreciation Rights tied to common stock at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to award terms. He also acquired 5,706 shares of common stock as a stock award, with related restricted stock units vesting 50% on the same future dates. To cover tax obligations from the vesting of prior performance stock units and restricted stock units, 42,820 shares of common stock were withheld rather than sold in the open market, through three F-code transactions at a reference price of $150.72 per share. After these awards and tax withholdings, Ackerman directly holds 183,905 shares of DaVita common stock, reflecting ongoing equity-based compensation and associated tax settlements rather than discretionary open-market trades.
DaVita Inc. director Adam H. Schechter received a grant of 332 shares of common stock on March 15, 2026, as a non-cash award. The shares were acquired at a stated price of $0.00 per share and increased his directly held position to 5,442 shares of DaVita common stock.
Moore Gregory J. reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. director Gregory J. Moore received an equity award of 332 shares of Common Stock on March 15, 2026. The shares were granted at no cash cost per share, indicating a compensation-related award rather than an open-market purchase. Following this grant, Moore directly holds 7,563 DaVita shares.
DaVita Inc. Chief Legal & Public Affairs Officer Kathleen Alyce Waters reported equity compensation grants and related tax withholdings. She received 8,610 stock appreciation rights tied to an equal number of common shares at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030, subject to award terms. She also acquired 3,185 restricted stock units that are scheduled to vest on the same dates.
To cover tax obligations from the vesting of previously granted performance stock units and restricted stock units, 33,863 shares of common stock were withheld at $150.72 per share through several F-code transactions. Following these compensation-related grants and withholdings, Waters directly holds 124,599 shares of DaVita common stock.
DaVita Inc.’s Chief Compliance Officer, James O. Hearty, reported equity compensation and related tax withholding transactions. He received a grant of 3,050 stock appreciation rights tied to Common Stock at an exercise price of $150.72 per share, scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030.
He also acquired 1,128 shares of Common Stock as a share-based award, with the related restricted stock units scheduled to vest 50% on March 15, 2029 and 50% on March 15, 2030. In separate transactions, a total of 11,578 shares of Common Stock were withheld at $150.72 per share to satisfy tax withholding obligations upon vesting of performance stock units and earlier restricted stock units. After these compensation and tax-withholding entries, Hearty directly holds 38,137 shares of DaVita Common Stock.
DaVita Inc. director Wendy Lee Schoppert received a compensation-related stock award. On March 15, 2026, she acquired 332 shares of DaVita common stock with no purchase price, reported as a grant or similar award. Following this award, she directly held 332 shares and indirectly held 3,305 shares through the Wendy L. Schoppert Revocable Trust.
DaVita Inc. Chief Compliance Officer James O. Hearty reported equity compensation awards rather than market trades. On March 10, 2026, he acquired 1,756 shares of DaVita common stock and separately 20,533 shares, both at no cash price, as part of performance-based stock awards.
According to the footnotes, these shares relate to performance stock units granted on March 15, 2022 and March 15, 2023, with 100% of each award scheduled to vest on March 15, 2026. Following these transactions, his reported direct holdings increased to 28,054 shares and 48,587 shares in the respective line items.
ACKERMAN JOEL reported acquisition or exercise transactions in this Form 4 filing.
DaVita Inc. insider filing shows equity awards to its CFO. Joel Ackerman, CFO and Treasurer of DaVita Inc., received two grants of common stock, covering 6,585 and 65,997 shares at no cost, as part of performance stock unit awards. These shares relate to performance stock units granted on March 15, 2022 and March 15, 2023, of which 100% will vest on March 15, 2026. Following these awards, he directly holds 221,019 shares of DaVita common stock.
DaVita Inc. Chief Legal & Public Affairs Officer Kathleen Alyce Waters reported two stock awards of common shares. On March 10, 2026, she acquired 4,829 shares of DaVita common stock at a price of $0.00 per share and separately acquired 51,330 additional shares, also at $0.00 per share.
Footnotes explain these shares were received upon satisfaction of criteria for performance stock units granted on March 15, 2022 and March 15, 2023, with 100% of each award scheduled to vest on March 15, 2026. Following these acquisitions, Waters directly holds 155,277 shares of DaVita common stock.